RxDoctor Payments Data

Anthony Tam, MD

Internal Medicine · New York, NYNPI 1053687491

Payments from drug & device makers

$4,505in general payments, 2019–2025

Across 195 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Amarin Pharma, Inc.$791
  • GSK$545
  • Lilly USA, LLC$231
  • AbbVie$226
  • Esperion Therapeutics, Inc.$207
  • plus $777 from 12 others

What the payments were for

  • Food & beverage$4,505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,505 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$79,470
Medicare patients
117
Services billed
1,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin213$271,377
JanuviaSitagliptin Phosphate247$262,990
FarxigaDapagliflozin Propanediol153$165,203
VemlidyTenofovir Alafenamide93$144,272
Diclofenac Epolamine186$133,328
RybelsusSemaglutide90$130,344
TradjentaLinagliptin99$101,988
EliquisApixaban53$56,846
XareltoRivaroxaban62$56,420
JanumetSitagliptin Phos/Metformin Hcl53$53,915
OzempicSemaglutide50$51,711
ProliaDenosumab16$27,851
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$25,983
VascepaIcosapent Ethyl36$22,391
EntrestoSacubitril/Valsartan16$21,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat$83$397,980356 claims
AstraZenecaFarxiga, Nexium, Breztri Aerosphere, Symbicort$176$204,163273 claims
Novo NordiskRybelsus, Ozempic$145$182,055140 claims
GileadVemlidy$1,728$144,27293 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Shingrix$545$53,486126 claims
AmgenProlia$128$27,85116 claims
Kowa Pharmaceuticals America, Inc.Livalo$35$12,39213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →